Limits...
Clinicopathologic analysis of localized nasal/paranasal diffuse large B-cell lymphoma.

Toda H, Sato Y, Takata K, Orita Y, Asano N, Yoshino T - PLoS ONE (2013)

Bottom Line: According to both Hans' and Choi's algorithms, the non-GCB type was predominant.Nevertheless, prognosis was good.In conclusion, although the non-GCB subtype is thought to show poor prognosis, in our study, the prognosis for localized nasal/paranasal DLBCL patients was good irrespective of subclassification.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.

ABSTRACT
Diffuse large B-cell lymphoma (DLBCL) comprises 2 molecularly distinct subgroups of non-germinal center B-cell-like (non-GCB) and germinal center B-cell-like (GCB) DLBCLs, with the former showing relatively poor prognosis. In the present study, we analyzed the clinicopathological features of 39 patients with localized nasal/paranasal DLBCL. Immunohistochemistry-based subclassification revealed that 11 patients (28%) were of the GCB-type according to Hans' algorithm and 11 (28%) were of the GCB-type according to Choi's algorithm. According to both Hans' and Choi's algorithms, the non-GCB type was predominant. Nevertheless, prognosis was good. Overall survival did not differ significantly between the GCB and non-GCB subgroups (Hans' algorithm: p = 0.57, Choi's algorithm: p = 0.99). Furthermore, the prognosis of localized nasal/paranasal DLBCL was better than that of other localized extranodal DLBCLs. The prognosis of extranodal DLBCL is usually considered poorer than that of nodal DLBCL. However, in our study, no difference was noted between patients with localized nasal/paranasal DLBCL and patients with localized nodal DLBCL. In conclusion, although the non-GCB subtype is thought to show poor prognosis, in our study, the prognosis for localized nasal/paranasal DLBCL patients was good irrespective of subclassification.

Show MeSH

Related in: MedlinePlus

Distribution of GCB and non-GCB type according to Hans et al. and Choi et al.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3585191&req=5

pone-0057677-g002: Distribution of GCB and non-GCB type according to Hans et al. and Choi et al.

Mentions: Table 4 summarizes the phenotypic features of the localized nasal/paranasal DLBCL patients. The B-cell immunophenotype of the lymphomas was confirmed by immunoreactivity with antibodies to CD20 in 39 cases. Although no cases were positive for CD5, 8 (21%) were positive for CD10 and 25 (64%) were positive for BCL6. For MUM1 staining, 28 cases (72%) were positive according to Hans’ algorithm and 24 cases (62%) were positive according to Choi’s algorithm. Furthermore, 29 cases (74%) were positive for FoxP1 and 12 (31%) were positive for GCET1. Of the 11 cases (28%) classified as GCB- type according to Hans’ algorithm, 8 were CD10-positive cases (20%), and 3 were CD10-negative, BCL6-positive, MUM1-negative cases (8%). Of the 11 (28%) classified as GCB- type according to Choi’s algorithm, 3 were GCET1-positive, MUM1-negative cases (8%); 5 were GCET1-negative, CD10-positive cases (13%); and 3 GCET1-negative, CD10-negative, BCL6-positive, FoxP1-negative cases (8%). Of the 28 cases (72%) classified as the non-GCB- type according to Hans’ algorithm, 12 were CD10-negative, BCL6-negative cases (31%) and 16 were CD10-negative, BCL6-positive, MUM1-positive cases (41%). Of the 28 cases (72%) classified as the non-GCB- type according to Choi’s algorithm, 9 were GCET1-positive, MUM1-positive cases (23%); 8 were GCET1-negative, CD10-negative, BCL6-positive, FoxP1-positive cases (20%); and 11 were GCET1-negative, CD10-negative, BCL6-negative cases (28%) (Fig. 2). The non-GCB- type was dominant according to both algorithms, but the prognosis for these cases was good. Overall survival did not differ significantly between the non-GCB type and GCB type groups (p = 0.57, Hans’ algorithm, p = 0.99, Choi’s algorithm) (Fig. 3).


Clinicopathologic analysis of localized nasal/paranasal diffuse large B-cell lymphoma.

Toda H, Sato Y, Takata K, Orita Y, Asano N, Yoshino T - PLoS ONE (2013)

Distribution of GCB and non-GCB type according to Hans et al. and Choi et al.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3585191&req=5

pone-0057677-g002: Distribution of GCB and non-GCB type according to Hans et al. and Choi et al.
Mentions: Table 4 summarizes the phenotypic features of the localized nasal/paranasal DLBCL patients. The B-cell immunophenotype of the lymphomas was confirmed by immunoreactivity with antibodies to CD20 in 39 cases. Although no cases were positive for CD5, 8 (21%) were positive for CD10 and 25 (64%) were positive for BCL6. For MUM1 staining, 28 cases (72%) were positive according to Hans’ algorithm and 24 cases (62%) were positive according to Choi’s algorithm. Furthermore, 29 cases (74%) were positive for FoxP1 and 12 (31%) were positive for GCET1. Of the 11 cases (28%) classified as GCB- type according to Hans’ algorithm, 8 were CD10-positive cases (20%), and 3 were CD10-negative, BCL6-positive, MUM1-negative cases (8%). Of the 11 (28%) classified as GCB- type according to Choi’s algorithm, 3 were GCET1-positive, MUM1-negative cases (8%); 5 were GCET1-negative, CD10-positive cases (13%); and 3 GCET1-negative, CD10-negative, BCL6-positive, FoxP1-negative cases (8%). Of the 28 cases (72%) classified as the non-GCB- type according to Hans’ algorithm, 12 were CD10-negative, BCL6-negative cases (31%) and 16 were CD10-negative, BCL6-positive, MUM1-positive cases (41%). Of the 28 cases (72%) classified as the non-GCB- type according to Choi’s algorithm, 9 were GCET1-positive, MUM1-positive cases (23%); 8 were GCET1-negative, CD10-negative, BCL6-positive, FoxP1-positive cases (20%); and 11 were GCET1-negative, CD10-negative, BCL6-negative cases (28%) (Fig. 2). The non-GCB- type was dominant according to both algorithms, but the prognosis for these cases was good. Overall survival did not differ significantly between the non-GCB type and GCB type groups (p = 0.57, Hans’ algorithm, p = 0.99, Choi’s algorithm) (Fig. 3).

Bottom Line: According to both Hans' and Choi's algorithms, the non-GCB type was predominant.Nevertheless, prognosis was good.In conclusion, although the non-GCB subtype is thought to show poor prognosis, in our study, the prognosis for localized nasal/paranasal DLBCL patients was good irrespective of subclassification.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.

ABSTRACT
Diffuse large B-cell lymphoma (DLBCL) comprises 2 molecularly distinct subgroups of non-germinal center B-cell-like (non-GCB) and germinal center B-cell-like (GCB) DLBCLs, with the former showing relatively poor prognosis. In the present study, we analyzed the clinicopathological features of 39 patients with localized nasal/paranasal DLBCL. Immunohistochemistry-based subclassification revealed that 11 patients (28%) were of the GCB-type according to Hans' algorithm and 11 (28%) were of the GCB-type according to Choi's algorithm. According to both Hans' and Choi's algorithms, the non-GCB type was predominant. Nevertheless, prognosis was good. Overall survival did not differ significantly between the GCB and non-GCB subgroups (Hans' algorithm: p = 0.57, Choi's algorithm: p = 0.99). Furthermore, the prognosis of localized nasal/paranasal DLBCL was better than that of other localized extranodal DLBCLs. The prognosis of extranodal DLBCL is usually considered poorer than that of nodal DLBCL. However, in our study, no difference was noted between patients with localized nasal/paranasal DLBCL and patients with localized nodal DLBCL. In conclusion, although the non-GCB subtype is thought to show poor prognosis, in our study, the prognosis for localized nasal/paranasal DLBCL patients was good irrespective of subclassification.

Show MeSH
Related in: MedlinePlus